Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 1.65 is 29% above its 5-year average of 1.28, around the middle of its 5-year range (0.10–2.69).
As of the fiscal period ended Tuesday, June 30, 2026. 3.55% below its 12-month average of 1.71.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 1.65.
CURRENT RATIO
1.65
CURRENT RATIO AVG TTM
1.71
CURRENT RATIO AVG 3Y
1.51
CURRENT RATIO AVG 5Y
1.28
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-3.55%
CURRENT VS 3Y AVG
+8.86%
CURRENT VS 5Y AVG
+28.83%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.75
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
-56.12%
vs the sector median at left
Market Cap
$2.07B
Current Ratio
11.82
TTM Avg
14.70
3Y Avg
15.08
5Y Avg
16.52
Market Cap
$2.06B
Current Ratio
16.95
TTM Avg
14.04
3Y Avg
14.77
5Y Avg
14.32
Market Cap
$2.08B
Current Ratio
10.92
TTM Avg
19.66
3Y Avg
12.98
5Y Avg
14.20
Market Cap
$2.11B
Current Ratio
1.69
TTM Avg
1.73
3Y Avg
1.64
5Y Avg
1.89
Market Cap
$2.02B
Current Ratio
2.32
TTM Avg
2.34
3Y Avg
3.23
5Y Avg
3.57
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alvotech (ALVO) | $2.07B | 1.65 | 1.71 | 1.51 | 1.28 |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.07B | 11.82 | 14.70 | 15.08 | 16.52 |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | 16.95 | 14.04 | 14.77 | 14.32 |
| Vera Therapeutics, Inc. (VERA)vs › | $2.08B | 10.92 | 19.66 | 12.98 | 14.20 |
| Vericel Corporation (VCEL)vs › | $2.05B | 5.04 | 4.63 | 4.69 | 5.05 |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 1.69 | 1.73 | 1.64 | 1.89 |
| Progyny, Inc. (PGNY)vs › | $2.03B | 2.14 | 2.76 | 2.92 | 2.79 |
| UroGen Pharma Ltd. (URGN)vs › | $2.02B | 3.80 | 5.01 | 5.21 | 5.22 |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | 2.32 | 2.34 | 3.23 | 3.57 |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | 18.83 | 6.22 | 3.45 | 3.57 |
Current Ratio
1.65
Quick Ratio
0.96
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 1.65 |
| 2026-03-31 | 1.76 |
| 2025-12-31 | 1.89 |
| 2025-09-30 | 1.42 |
| 2025-06-30 | 1.82 |
| 2025-03-31 | 1.73 |
| 2024-12-31 | 2.35 |
| 2024-09-30 | 2.69 |
| 2024-06-30 | 0.24 |
| 2024-03-31 | 1.18 |
| 2023-12-31 | 0.75 |
| 2023-08-31 | 1.22 |
| 2023-06-30 | 0.96 |
| 2023-03-31 | 1.68 |
| 2022-12-31 | 1.38 |
| 2022-09-30 | 0.76 |
| 2022-06-30 | 0.86 |
| 2022-03-31 | 0.10 |
| 2021-12-31 | 1.07 |
| 2021-09-30 | 0.30 |
| 2021-06-30 | 1.02 |
| 2021-03-31 | 1.80 |
| 2020-12-31 | 1.69 |
| 2020-09-30 | 24.06 |
| 2020-06-30 | 1.69 |
| 2020-03-31 | 1.69 |
| 2019-12-31 | 0.00 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
